Tony Berberabe, MPH

Articles

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

September 9th 2021

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward

September 8th 2021

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma

June 11th 2021

Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma.

Improved Responses Sustained With Pembrolizumab in Treatment-Naïve Melanoma, But Not in Rechallenged Patients

June 6th 2021

Patients with stage III melanoma who progressed following placebo-based treatment in the first part of the phase 3 EORTC 1325/KEYNOTE-054 trial and crossed over to receive pembrolizumab post-recurrence derived a 38.8% overall response rate and a 32% overall 3-year progression-free survival rate.

TNO155 Demonstrates Manageable Safety and Consistent SHP2 Inhibition in Advanced Solid Tumors

June 4th 2021

The investigational SHP2 inhibitor TNO155 demonstrated encouraging safety and tolerability, and consistent evidence of SHP2 inhibition in patients with advanced solid tumors.

Dostarlimab Triplet Shows Antitumor Activity, Tolerability in Ovarian Cancer

March 20th 2021

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer

February 13th 2021

February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

Ruxolitinib Induces Improved Responses in Chronic GVHD

February 12th 2021

February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.

Nab-Paclitaxel Noninferior to Docetaxel in Previously Treated NSCLC

January 29th 2021

January 29, 2021 - Nab-paclitaxel proved to be noninferior to docetaxel, having showcased improved progression-free survival, overall survival, and overall response rate in patients with previously treated advanced non–small cell lung cancer.

Axitinib/Octreotide Combo Fails to Improve PFS in Pancreatic NETs

January 17th 2021

January 17, 2021 - Axitinib plus octreotide LAR failed to demonstrate a significant improvement in progression-free survival (PFS) compared with placebo plus octreotide LAR in patients with advanced G1-2 extra-pancreatic neuroendocrine tumors.

Creating a Community Improves Outcomes in Myeloma

January 6th 2021

A community can be defined by any number of characteristics. In Lonial’s case, he has built a community of physicians who’ve come together to treat patients with multiple myeloma.

Pevonedistat/Azacitidine Demonstrates Improved Efficacy Vs Single-Agent Azacitidine in MDS

December 8th 2020

December 8, 2020 — Pevonedistat in combination with azacitidine improved overall survival and prolonged event-free survival compared with azacitidine monotherapy in patients with higher-risk myelodysplastic syndrome.

Belantamab Mafodotin Elicits Deep, Durable Responses in Heavily Pretreated Relapsed/Refractory Myeloma

December 6th 2020

December 6, 2020 — The antibody-drug conjugate belantamab mafodotin continued to showcase efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma, inducing durable responses even in those who had previously received 7 or more lines of therapy.

bb21217 Continues to Showcase Durable Responses in Multiple Myeloma

December 5th 2020

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Low-Dose Lenvatinib Shows Similar Safety to Standard Dose in RCC, But Noninferiority Cannot Be Claimed

November 7th 2020

A 14-mg dose of lenvatinib showed similar safety to the standard 18-mg dose of the agent, when used in combination with everolimus in the second-line treatment of patients with advanced renal cell carcinoma, but noninferiority could not be confirmed.

Quad Therapy Induces Deep Responses in Black Patients With Multiple Myeloma

October 16th 2020

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer

September 20th 2020

The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone

Higher PFS Rate Reported for Encorafenib/Binimetinib Combo Followed by Immunotherapy in Metastatic Melanoma

September 19th 2020

Early findings from a phase II efficacy and safety study may be the first step in developing a definitive rationale for sequencing targeted therapies and immunotherapies in patients with metastatic melanoma.

More Frequent Dosing of Lanreotide Autogel Delays the Use of More Toxic Treatments in Pancreatic, Midgut NETs

September 19th 2020

Improvements in disease-free survival and progression-free survival were observed in patients with progressive pancreatic or midgut neuroendocrine tumors whose frequency of dosing for lanreotide Autogel was increased from 120 mg every 28 days to every 14 days.